Over the past decade, the global bleeding disorders community has witnessed great strides in the research of new treatments and methods of care. During the...
When does a patient’s personal experience intersect with the successful delivery of treatment? Is it at the start of receiving care? Is it after treatment...
We have entered an era of unprecedented growth in treatment options for hemophilia. A number of new treatments have, or will soon, enter the market,...
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic hepatitis C infection. There have been...
New medications unveiled in the last two years have revolutionized the treatment of hepatitis C (HCV) drastically improving patients’ chances of a cure. The challenge...
In 2016 the World Federation of Hemophilia (WFH) is working with the global bleeding disorders community to focus on the theme of Treatment for All...
For many national hemophilia organizations, the path to improving hemophilia healthcare in their countries comes from the many contributions from both global and regional partners....
Every year, national aggregate data is collected from World Federation of Hemophilia (WFH) national member organizations (NMOs) and published in the Report on the WFH...
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
Over the last few decades, many of the World Federation of Hemophilia (WFH) national member organizations (NMOs) in Latin America have expanded their networks, become...
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...
During a visit to Morocco in October 2015, World Federation of Hemophilia (WFH) president Alain Weill, and a representative from the Moroccan Ministry of Health...